신경내분비종양(NET): 국가별 치료 선택지

임상시험 진행 중

• Preoperative catecholamine blockade; surgery; chemotherapy; radiofrequency ablation; cryoablation; radiation therapy; palliative therapy; clinical trials임상시험임상시험InvestigationalUnited States · No mutation biomarker required by fetched NCI framework; hereditary syndromes and genetic testing are discussed as risk/management context; Localized, regional, metastatic, unresectable, and recurrent pheochromocytoma/paraganglioma contexts. · NCI PDQ is an evidence summary, not a regulator or payer source. It notes limited phase 2 clinical-trial data and that survival impact is not known for many approaches. It does not provide a personalized sequence or eligibility determination. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific options require separate label sources. National Cancer Institute (NCI) — national cancer agency evidence summary
• Surgery; somatostatin analogues; hepatic-metastasis treatments; radionuclides including lutetium Lu 177 dotatate (Lutathera); symptomatic therapy; everolimus (Afinitor); sunitinib (Sutent); clinical trials임상시험임상시험InvestigationalUnited States · Somatostatin receptor (SSTR)-positive status for lutetium Lu 177 dotatate; non-functional status for GI/lung everolimus label context; no mutation biomarker required by fetched sources; Gastrointestinal NET treatment framework; SSTR-positive GEP-NETs in adults and pediatric patients 12 years and older; progressive pancreatic NET; progressive well-differentiated non-functional GI NET; unresectable, locally advanced, or metastatic settings as stated in labels. · NCI PDQ is an evidence summary and does not establish payer coverage. FDA/DailyMed labels do not imply individual eligibility, center access, receptor positivity, tumor grade, functional status, or sequencing among therapies. Sunitinib label context is pancreatic NET, not all GEP-NETs. Confidence/conflicts: High for U.S. evidence-summary and labeled indications; sequencing and reimbursement require separate local verification. DailyMed / U.S. FDA label — official drug label
• Surgery/adrenalectomy; phenoxybenzamine or similar preoperative blockade; MIBG radioisotope therapy; DOTATATE radionuclide therapy; external beam radiotherapy; CVD chemotherapy (cyclophosphamide, vincristine, dacarbazine); targeted drugs studied including sunitinib and cabozantinib; watch-and-wait/active surveillance; radiofrequency ablation and chemoembolisation임상시험임상시험InvestigationalUnited Kingdom · MIBG uptake for MIBG treatment; DOTATATE uptake for DOTATATE radionuclide therapy; no mutation biomarker required by fetched UK source; Non-spread disease; recurrent or spread phaeochromocytoma; MIBG-avid or DOTATATE-avid disease; bone spread symptom-control context; spread disease not responding to MIBG/DOTATATE. · Cancer Research UK is a patient-information source, not NICE/MHRA regulator guidance. It says DOTATATE treatment is newer and not available in all hospitals, and that targeted drugs have been studied but comparative effectiveness versus chemotherapy is uncertain. No claim is made for automatic NHS access. Confidence/conflicts: Medium-high for UK treatment-information framework; NICE/MHRA and hospital availability remain active gaps. Cancer Research UK — UK cancer information / treatment information
• Belzutifan / MK-6482 (Welireg)임상시험 · NCT04924075임상시험Trial only (NCT04924075)Japan · HIF-2alpha-related genetic alterations for one study cohort; VHL disease-associated tumor cohort; PPGL cohort does not require a mutation in the fetched registry summary; Advanced PPGL and other study cohorts including pNET, VHL-associated tumors, advanced wild-type GIST, or HIF-2alpha-related solid tumors. · Registry listing does not establish PMDA or Russian regulator approval, reimbursement, routine access, or individual eligibility. The study has multiple cohorts, so cohort assignment must be confirmed for PPGL. Confidence/conflicts: High for registry-listed Japan/Russia sites; local approval/access unverified. ClinicalTrials.gov — clinical-trial registry
• PDR001; sunitinib임상시험 · NCT02955069임상시험Trial only (registry)Japan · Non-functional status for well-differentiated pancreatic/GI/thoracic NET cohorts in NCT02955069; no mutation biomarker required by fetched Japan registry records; Advanced or metastatic well-differentiated non-functional pancreatic/GI/thoracic NET; poorly differentiated GEP-NEC; advanced well-differentiated pancreatic NET. · Registry records are completed and do not establish PMDA approval, reimbursement, current access, or individual eligibility. PDR001 is investigational in this context; sunitinib trial listing is not a current Japanese label source. Confidence/conflicts: Medium-high for Japan registry-listed trial activity; current PMDA status remains unverified. ClinicalTrials.gov — clinical-trial registry
• Belzutifan / MK-6482; phenoxybenzamine preoperative alpha-adrenergic blockade; RAD001 (everolimus); adrenal-disease cohort hormone and imaging study임상시험 · NCT04924075임상시험Trial only (registry)Korea · No mutation biomarker required by fetched Korea registry records; Advanced PPGL trial context; normotensive pheochromocytoma perioperative management; pheochromocytoma/extra-adrenal paraganglioma targeted therapy study; adrenal disease evidence-generation contexts. · Registry records do not establish MFDS approval, reimbursement, routine access, or standard-of-care changes. The alpha-blockade study tests omission in normotensive pheochromocytoma and should not be generalized to catecholamine-secreting or hypertensive disease. Confidence/conflicts: High for Korea registry-listed PPGL activity; MFDS/routine access remains unverified. ClinicalTrials.gov — clinical-trial registry
• Lutetium Lu 177 dotatate / Lutathera; TEMCAP (temozolomide/capecitabine); lanreotide autogel; RYZ101; everolimus; sunitinib; octreotide; lanreotide임상시험 · NCT04946305임상시험Trial only (registry)Korea · SSTR-positive status for Lutathera and Lu-DOTA-TATE/RYZ101 studies; low Ki-67 grade 3 context for TEMCAP study; no mutation biomarker required by fetched Korea records; SSTR-positive GEP-NET post-marketing surveillance; grade 3 low Ki-67 GEP-NET; inoperable SSTR-positive well-differentiated GEP-NET after Lu-177 SSA; grade 1/2 advanced GEP-NET; grade 2/3 advanced GEP-NET. · Registry records do not establish MFDS approval, reimbursement, routine access, active enrollment for all studies, or individual eligibility. The Lutathera post-marketing surveillance record suggests local post-approval safety monitoring but is not itself a regulator label. Confidence/conflicts: High for Korea registry-listed GEP-NET activity; MFDS approval and reimbursement require regulator verification. ClinicalTrials.gov — clinical-trial registry
• Belzutifan / MK-6482; anlotinib hydrochloride; temozolomide; 18F-MFBG; 68Ga-DOTATATE임상시험 · NCT04924075임상시험Trial only (registry)China · No mutation biomarker required by fetched China treatment registry records; imaging studies involve 18F-MFBG and 68Ga-DOTATATE uptake evaluation; Advanced PPGL; neoadjuvant PPGL; metastatic or locally advanced PPGL; metastatic malignant pheochromocytoma/paraganglioma; imaging evaluation. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Some China records have unknown status despite listed recruiting site status. Imaging studies support diagnostic/selection context, not therapeutic availability. Confidence/conflicts: High for China registry-listed PPGL activity; NMPA approval/access not established. ClinicalTrials.gov — clinical-trial registry
• Octreotide subcutaneous injection (SYHX2008) and Sandostatin LAR; 177Lu-edotreotide PRRT; CAPTEM; everolimus; FOLFOX; famitinib; lutetium [177Lu] oxodotreotide injection; sirolimus albumin-bound plus octreotide long-acting injection; lanreotide autogel임상시험 · NCT06505395임상시험Trial only (registry)China · Somatostatin receptor-positive status for Lu-177 oxodotreotide studies where specified; no mutation biomarker required by fetched China registry records; Advanced/metastatic GEP-NET; well-differentiated aggressive grade 2/3 GEP-NET; locally advanced/metastatic SSTR-positive G2/G3 GEP-NET; metastatic GEP-NET; Chinese GEP-NET participant treatment studies. · Registry records do not establish NMPA approval, reimbursement, routine availability, active enrollment for all studies, or individual eligibility. One famitinib record is terminated and one Lu-177 dotatate record has unknown status. Confidence/conflicts: High for China registry-listed GEP-NET study activity; NMPA approval/access status unverified. ClinicalTrials.gov — clinical-trial registry
• Everolimus; pasireotide LAR; pasireotide; cabergoline; Sandostatin LAR Depot임상시험 · NCT01374451임상시험Trial only (registry)Thailand · No mutation biomarker required by fetched Thailand registry records; Advanced pancreatic NET; advanced pancreatic-origin neuroendocrine tumors; ongoing access context for patients benefiting from pasireotide in prior sponsored studies that included NET. · Thailand records are historical/completed or terminated and do not establish Thai FDA approval, reimbursement, current availability, or eligibility. The pasireotide access study includes multiple diseases and should not be interpreted as a Thailand NET-specific standard therapy source. Confidence/conflicts: Medium for Thailand historical trial/access activity; current Thai regulatory and routine availability status remains unverified. ClinicalTrials.gov — clinical-trial registry